Date: 2017-07-24
Type of information: Private placement
Company: Intralytix (USA - MA)
Investors: Lesaffre (France)
Amount: $17.5 million
Funding type: private placement
Planned used:
Others:
- • On July 24, 2017, Intralytix announced that it received $17.5 million in new equity funding from Lesaffre, a French family group. This investment marks the beginning of a close collaboration between both companies to develop and commercialize bacteriophage-based products, for various benefits in human health and in other areas of mutual interest. As a global key player in yeasts and fermentation, Lesaffre designs, manufactures and markets innovative solutions for Baking, Food taste & pleasure, Health care and Biotechnology. This new investment is perfectly in line with Lesaffre’s ongoing expansion strategy in nutrition and health.
Antoine Baule, Lesaffre’s CEO, added “We believe that bacteriophages technology, mastered by Intralytix, offers an exciting platform for developing various antimicrobial products that will help reduce antibiotic resistance. Intralytix is the leader in this field, and we look forward to working with their teams, developing new phage-based products and technologies and making them available to benefit customers worldwide.”
Therapeutic area: Infectious diseases
Is general: Yes
